Tennessee Oncology Earned FACT Accreditation

The practice became the first community site to meet new standards for delivering specialized immune cell therapies.

Updated on Sept. 29, 2026 in Cancer

Isometric editorial illustration of a sterile medical infusion pump in a clinical room, representing high-quality community healthcare standards. — Tennessee Oncology has become the first community-based practice to earn FACT accreditation for the delivery of specialized immune effector cell therapies. AI Illustration. Upload story photo >

Live Poll

Would you prefer receiving specialized cancer treatments at a local clinic rather than a distant hospital?

On September 1, 2026, Tennessee Oncology achieved accreditation under the Community IEC Standards, becoming the first community-based oncology practice to do so. This milestone reflects a shift in how advanced cellular therapies are managed outside of traditional academic hospital settings.

Why it matters

By meeting these standards, community-based clinics can provide complex immune effector cell treatments closer to home, which may help improve patient adherence and reduce travel burdens. This accreditation framework was established to expand the availability of these therapies while maintaining rigorous safety and quality oversight.

The Foundation for the Accreditation of Cellular Therapy (FACT) has accredited 346 programs worldwide since its 1996 founding. Tennessee Oncology is now the first community-based practice to meet the Community IEC Standards established in November 2025.

The players

Tennessee Oncology

A community-based oncology practice that delivers cancer care to residents across the state.

Foundation for the Accreditation of Cellular Therapy

An international organization that sets quality standards for hematopoietic progenitor cell and immune effector cell therapies.

OneOncology

A network supporting community oncology practices that is currently assisting four additional sites in pursuing accreditation.

The details

The Community IEC Standards were developed by a multistakeholder working group to adapt existing international protocols for cellular therapy to the community oncology environment. These standards ensure that practices maintain the same quality and safety benchmarks for immune effector cell treatments as major research centers. By applying these criteria, community clinics can safely administer specialized therapies locally.

FACT was established in 1996.
The Community IEC Standards were published in November 2025.
Tennessee Oncology achieved its accreditation on September 1, 2026.

Health Landscape

The adaptation of the FACT-JACIE International Standards for Immune Effector Cells represents a broadening of clinical reach for complex cancer immunotherapies. This movement reflects a broader trend of shifting advanced cellular treatments from research institutions to community-based settings.

If you are undergoing cancer treatment, this development means that specialized therapies may become more accessible within your local community. It is worth discussing with your oncology team whether your specific treatment plan involves therapies that require this type of accredited oversight.

The takeaway

The move toward community-based accreditation for immune cell therapies could simplify access for patients needing advanced cancer care. Patients should consult their physicians to understand if their treatment options include therapies administered under these safety-focused national standards.